慢性髓系白血病与结核病共病研究进展

doi:10.19983/j.issn.2096-8493.20220108

摘要/Abstract

摘要：

慢性髓系白血病是第一种发现与基因改变有关的血液恶性肿瘤,通过酪氨酸激酶抑制剂的靶向治疗可以获得功能性治愈。然而,当前仍有一些问题限制了它的治疗,合并结核病是其中一个重要因素。抗结核药物可通过改变肝酶代谢影响其他药物的药代动力学,并对慢性髓系白血病药物的靶向治疗构成挑战。未来仍然需要进一步的研究和专门的随机对照试验,以制定更为明确和充分的治疗指南,提高对慢性髓系白血病与结核病共病患者的治疗疗效。

关键词: 白血病, 髓系, 慢性, 结核, 共病现象, 药代动力学

Abstract:

Chronic myeloid leukemia is the first hematological malignancy found to be associated with genetic alterations. It can be functionally cured by targeted therapy with tyrosine kinase inhibitors. However, there are some problems that limit the treatment, and tuberculosis is one of the important factors. Anti-tuberculosis drugs can affect the pharmacokinetics of other drugs by altering the metabolism of liver enzymes and challenge the targeted treatment of chronic myeloid leukemia drugs. In the future, further research and special randomized controlled trials are still needed to formulate more clear and sufficient treatment guidelines, to improve the therapeutic efficacy of such patients.

Key words: Leukemia, myelogenous, chronic, Tuberculosis, Comorbidity, Pharmacokinetics

中图分类号:

R551
R52

刘玉坤, 郭智. 慢性髓系白血病与结核病共病研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 325-327. doi: 10.19983/j.issn.2096-8493.20220108

Liu Yukun, Guo Zhi. Research progress of chronic myeloid leukemia complicated with tuberculosis[J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 325-327. doi: 10.19983/j.issn.2096-8493.20220108

参考文献 20

[1]	Hughes A, Yong ASM. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Front Immunol, 2017, 8: 469. doi: 10.3389/fimmu.2017.00469. doi: 10.3389/fimmu.2017.00469 pmid: 28484463
[2]	中华医学会血液学分会.慢性髓性白血病中国诊断与治疗指南(2020年版). 中华血液学杂志, 2020, 41 (5): 353-364. doi: 10.3760/cma.j.issn.0253-2727.2020.05.001. doi: 10.3760/cma.j.issn.0253-2727.2020.05.001
[3]	Granatowicz A, Piatek CI, Moschiano E, et al. An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J Fam Med, 2015, 36(5):197-202. doi: 10.4082/kjfm.2015.36.5.197. doi: 10.4082/kjfm.2015.36.5.197 pmid: 26435808
[4]	Glaziou P, Sismanidis C, Floyd K, et al. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med, 2014, 5(2): a017798. doi: 10.1101/cshperspect.a017798. doi: 10.1101/cshperspect.a017798
[5]	董航, 杜映荣. 糖尿病与肺结核共病的临床研究进展. 结核与肺部疾病杂志, 2022, 3(1): 65-69. doi: 10.19983/j.issn.2096-8493.20210121. doi: 10.19983/j.issn.2096-8493.20210121
[6]	董晓伟, 刘玉琴, 卢水华. 结核分枝杆菌潜伏感染的治疗: 利大于弊还是弊大于利. 中国实用内科杂志, 2019, 39(5): 443-446. doi: 10.19538/j.nk2019050112. doi: 10.19538/j.nk2019050112
[7]	李虹艾, 李帮涛, 刘鹂, 等. 国内白血病合并结核病临床病例分析. 中国感染与化疗杂志, 2019, 19(3): 243-247. doi: 10.16718/j.1009-7708.2019.03.003. doi: 10.16718/j.1009-7708.2019.03.003
[8]	Al-Anazi KA, Al-Jasser AM, Evans DA. Infections caused by mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve year retrospective study. Ann Clin Microbiol Antimicrob, 2007, 6: 16. doi: 10.1186/1476-0711-6-16. doi: 10.1186/1476-0711-6-16 URL
[9]	Chen CY, Sheng WH, Cheng A, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis, 2011, 11: 324. doi: 10.1186/1471-2334-11-324. doi: 10.1186/1471-2334-11-324 URL
[10]	Shu CC, Liao KM, Chen YC, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep, 2019, 9(1): 11901. doi: 10.1038/s41598-019-48395-8. doi: 10.1038/s41598-019-48395-8 URL
[11]	Liu CJ, Hong YC, Teng CJ, et al. Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan. Int J Cancer, 2015, 136(8):1881-1887. doi: 10.1002/ijc.29201. doi: 10.1002/ijc.29201 URL
[12]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43 (11): 918-946. doi: 10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[13]	中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019, 42 (5): 343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
[14]	Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore), 2017, 96(28): e7482. doi: 10.1097/MD.0000000000007482. doi: 10.1097/MD.0000000000007482
[15]	Cao L, Greenblatt DJ, Kwara A. Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes. Drug Metab Dispos, 2017, 45(9):1035-1043. doi: 10.1124/dmd.117.076034. doi: 10.1124/dmd.117.076034 URL
[16]	Climent N, Plana M. Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Front Pharmacol, 2019, 10:1232. doi: 10.3389/fphar.2019.01232. doi: 10.3389/fphar.2019.01232 pmid: 31680987
[17]	Ghadyalpatil N, Prabhash K, Menon H, et al.Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib J Clin Oncol, 2010,28(15 suppl): 6594. doi: 10.1200/jco.2010.28.15_suppl.6594. doi: 10.1200/jco.2010.28.15_suppl.6594
[18]	Bhuiyan TM, Rahman MM, Hoque MN, et al. Peritoneal Tuberculosis in a Patient with Chronic Myeloid Leukemia and Diabetes Mellitus: A Diagnostic Dilemma. BIRDEM Medical Journal, 2013, 3(2): 281-297. doi: 10.3329/birdem.v3i2.17217. doi: 10.3329/birdem.v3i2.17217
[19]	Bhatnagar V, Adelakun A, Kendall T, et al. Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. Arch Iran Med, 2015, 18(1):65-68. doi: 0151801/AIM.0015 pmid: 25556390
[20]	Kim DJ, Jeong S, Kong SG, et al. First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. Blood Res, 2019, 54(2):151-153. doi: 10.5045/br.2019.54.2.151. doi: 10.5045/br.2019.54.2.151 URL